Nuplazid Safety Review: Blast From the Past Or Preview Of Future Terrors?

Fueled by Congress, media attention, reevaluation of Acadia's Parkinson's drug feels like a scandal from pharma's primary care era – but is also a glimpse of what things might look like for industry if Democrats retake the House. 

Side-view mirror on car looking back
Which way is the safety culture going?

The US FDA's reevaluation of the safety of Acadia Pharmaceuticals Inc.'s Nuplazid (pimavanserin) should remind pharmaceutical executives of safety crises from years past – but also serve as a warning about what firms might face if Democrats succeed in taking back the House in the midterm elections this fall.

Nuplazid, a Parkinson's drug approved in 2016, was the subject of intense questions by Rep. Rosa DeLauro during an April...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet